Page last updated: 2024-08-24

topotecan and Lassitude

topotecan has been researched along with Lassitude in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (20.00)18.2507
2000's7 (70.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW1
Borad, MJ; Curtis, KK; Fitch, TR; Griffin, PP; Hartney, JT; Jewell, RC; Lebowitz, PF; Northfelt, DW; Park, JW1
Leath, CA; Phippen, NT1
Bélanger, K; Bergeron, J; Burdette-Radoux, S; Cairncross, G; Eisenhauer, E; Forsyth, P; Gertler, S; Ludwin, S; MacDonald, D; Soulières, D; Wainman, N1
Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA1
Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C1
Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD1
Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N1
Beckman, RA; Gore, M; Hearn, S; Lane, SR; Ross, G; Rustin, G; Schüller, J1
Aalders, JG; Beijnen, JH; Bos, AM; de Vries, EG; Hofstra, LS; Mulder, NH; Rosing, H; van der Zee, AG; Willemse, PH1

Trials

9 trial(s) available for topotecan and Lassitude

ArticleYear
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult

2009
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan

2010
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.
    Investigational new drugs, 2003, Volume: 21, Issue:4

    Topics: Astrocytoma; Fatigue; Humans; Infusions, Intravenous; Oligodendroglioma; Topotecan

2003
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:6

    Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome

2006
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting

2007
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome

1998
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan

1999
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
    British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8

    Topics: Abdominal Pain; Adult; Aged; Alopecia; Antineoplastic Agents; Diarrhea; Fatigue; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Ovarian Neoplasms; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome; Vomiting

2001
A phase I and pharmacokinetic study of intraperitoneal topotecan.
    British journal of cancer, 2001, Nov-30, Volume: 85, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Fatigue; Female; Humans; Injections, Intraperitoneal; Metabolic Clearance Rate; Middle Aged; Nausea; Ovarian Neoplasms; Topotecan; Treatment Outcome; Vomiting

2001

Other Studies

1 other study(ies) available for topotecan and Lassitude

ArticleYear
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
    The Journal of reproductive medicine, 2009, Volume: 54, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Thalidomide; Topotecan

2009